Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Research works printed but not linked: 1
- 2002, Cancer Research, 62, 5749
Cited by
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H.-W. (2016) · Cancers · doi:10.3390/cancers8020022 · Cited by 581
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., Matsuki, M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212513 · Cited by 460
Self-citationTaylor, M. H., Lee, C.-H., Makker, V., Rasco, D., Dutcus, C. E., Wu, J., Stepan, D. E., Shumaker, R. C., & Motzer, R. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 435
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
Recent progress in treatment of hepatocellular carcinoma.
Chen, Z., Xie, H., Hu, M., Huang, T., Hu, Y., Sang, N., & Zhao, Y. (2020) · PubMed Central · Cited by 359
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Self-citationLenvatinib: A Review in Hepatocellular Carcinoma
Al-Salama, Z. T., Syed, Y. Y., & Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01116-x · Cited by 318
Kudo, M., Han, K.-H., Ye, S.-L., Zhou, J., Huang, Y.-H., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
Self-citationLenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Zhao, Y., Zhang, Y.-N., Wang, K.-T., & Chen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188391 · Cited by 278
Wang, J., Yu, H., Dong, W., Zhang, C., Hu, M., Ma, W., Jiang, X., Li, H., Yang, P., & Xiang, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.041 · Cited by 277
Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori‐Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1517 · Cited by 266
Self-citationTargeted therapy for hepatocellular carcinoma: Challenges and opportunities
Chen, S., Cao, Q., Wen, W., & Wang, H. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114428 · Cited by 255
Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1127 · Cited by 247
Self-citationTchekmedyian, V., Sherman, E. J., Dunn, L., Tran, C., Baxi, S., Katabi, N., Antonescu, C. R., Ostrovnaya, I., Haque, S. S., Pfister, D. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01859 · Cited by 243
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M. D., & Hurria, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6472 · Cited by 209
Lenvatinib: Role in thyroid cancer and other solid tumors
Cabanillas, M. E., & Habra, M. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.003 · Cited by 208
He, M.-K., Liang, R.-B., Zhao, Y., Xu, Y.-J., Chen, H.-W., Zhou, Y.-M., Lai, Z.-C., Xu, L., Wei, W., Zhang, Y.-J., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211002720 · Cited by 207
Lenvatinib for Anaplastic Thyroid Cancer
Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., Minami, H., Imamura, Y., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00025 · Cited by 205
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y., & Wei, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13009 · Cited by 189
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Ikeda, M., Okusaka, T., Mitsunaga, S., Ueno, H., Tamai, T., Suzuki, T., Hayato, S., Kadowaki, T., Okita, K., & Kumada, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1354 · Cited by 186
Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2426 · Cited by 184
Self-citationSystemic Therapy for Hepatocellular Carcinoma: Latest Advances
Kudo, M. (2018) · Cancers · doi:10.3390/cancers10110412 · Cited by 172
Mahdy, H. A., Ibrahim, M. K., Metwaly, A. M., Belal, A., Mehany, A. B. M., El-Gamal, K. M. A., El-Sharkawy, A., Elhendawy, M. A., Radwan, M. M., Elsohly, M. A., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103422 · Cited by 171
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
Tümen, D., Heumann, P., Gülow, K., Demirci, C.-N., Cosma, L.-S., Müller, M., & Kandulski, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123202 · Cited by 170
Lai, Z., He, M., Bu, X., Xu, Y.-J., Huang, Y., Wen, D., Li, Q., Xu, L., Zhang, Y., Wei, W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.005 · Cited by 170
Platelet‐derived growth factor ( PDGF ) signalling in cancer: rapidly emerging signalling landscape
Farooqi, A. A., & Siddik, Z. H. (2015) · Cell Biochemistry and Function · doi:10.1002/cbf.3120 · Cited by 161
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000502905 · Cited by 160
Molecular targets of tyrosine kinase inhibitors in thyroid cancer
Fallahi, P., Ferrari, S. M., Galdiero, M. R., Varricchi, G., Elia, G., Ragusa, F., Paparo, S. R., Benvenga, S., & Antonelli, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.013 · Cited by 160
Cabanillas, M. E., & Takahashi, S. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.11.004 · Cited by 141
Novel treatments for anaplastic thyroid carcinoma
Ferrari, S. M., Elia, G., Ragusa, F., Ruffilli, I., Motta, C. L., Paparo, S. R., Patrizio, A., Vita, R., Benvenga, S., Materazzi, G., et al. (2020) · Gland Surgery · doi:10.21037/gs.2019.10.18 · Cited by 140
Targeting FGFR for cancer therapy
Zhang, P., Yue, L., Leng, Q., Chen, C., Gan, C., Ye, T., & Cao, D. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01558-1 · Cited by 139
Capozzi, M., Divitiis, C. D., Ottaiano, A., von Arx, C., Scala, S., Tatangelo, F., Delrio, P., & Tafuto, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188316 · Cited by 138
Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
Kudo, M. (2018) · Liver Cancer · doi:10.1159/000487148 · Cited by 135
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 135
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
Hida, T., Velcheti, V., Reckamp, K. L., Nokihara, H., Sachdev, P., Kubota, T., Nakada, T., Dutcus, C. E., Ren, M., & Tamura, T. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.011 · Cited by 128
Chen, Y., Dai, S., Cheng, C., & Chen, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01647-1 · Cited by 121
RET signaling pathway and RET inhibitors in human cancer
Regua, A. T., Najjar, M. K., & Lo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932353 · Cited by 119
Tahara, M., Brose, M. S., Wirth, L. J., Suzuki, T., Miyagishi, H., Fujino, K., Dutcus, C. E., & Gianoukakis, A. G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.002 · Cited by 115
Gunda, V., Gigliotti, B., Ashry, T., Ndishabandi, D., McCarthy, M., Zhou, Z., Amin, S., Lee, K. E., Stork, T., Wirth, L., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32041 · Cited by 111
Lenvatinib: First Global Approval
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0383-0 · Cited by 103
Ueno, M., Ikeda, M., Sasaki, T., Nagashima, F., Mizuno, N., Shimizu, S., Ikezawa, H., Hayata, N., Nakajima, R., & Morizane, C. (2020) · BMC Cancer · doi:10.1186/s12885-020-07365-4 · Cited by 100
Prolonged duration of response in lenvatinib responders with thyroid cancer
Gianoukakis, A. G., Dutcus, C. E., Batty, N., Guo, M. D., & Baig, M. A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0049 · Cited by 98
Brose, M. S., Panaseykin, Y., Konda, B., de la Fouchardière, C., Hughes, B. G. M., Gianoukakis, A. G., Park, Y. J., Romanov, I., Krzyzanowska, M. K., Leboulleux, S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab731 · Cited by 98
Signaling pathways in liver cancer: pathogenesis and targeted therapy
Xue, Y., Ruan, Y., Wang, Y., Xiao, P., & Xu, J. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00184-0 · Cited by 97
Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET
Zschäbitz, S., & Grüllich, C. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_13 · Cited by 94
Finn, R. S., Kudo, M., Cheng, A., Wyrwicz, L. S., Ngan, R. K. C., Blanc, J., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4219 · Cited by 86
Self-citationPharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
Mattia, E. D., Cecchin, E., Guardascione, M., Foltran, L., Raimo, T. D., Angelini, F., D'Andrea, M. R., & Toffoli, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3870 · Cited by 86
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
French, J. D. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0398-9 · Cited by 85
Zhang, Q., Liu, X., Wei, S., Zhang, L., Tian, Y., Gao, Z., Jin, M., & Yan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751391 · Cited by 85
Lin, Y., Tan, C., Chen, C.-W., Ou, D., Cheng, A., & Hsu, C. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1673621 · Cited by 84
Hoshi, T., Miyano, S. W., Watanabe, H., Sonobe, R. M. K., Seki, Y., Ohta, E., Nomoto, K., Matsui, J., & Funahashi, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.02.015 · Cited by 84
Self-citationTahara, M., Schlumberger, M. J., Elisei, R., Habra, M. A., Kiyota, N., Paschke, R., Dutcus, C. E., Hihara, T., McGrath, S. M., Matijevic, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.013 · Cited by 84
Self-citationShimose, S., Iwamoto, H., Niizeki, T., Shirono, T., Noda, Y., Kamachi, N., Okamura, S., Nakano, M., Suga, H., Kuromatsu, R., et al. (2020) · Cancers · doi:10.3390/cancers12071867 · Cited by 84
Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
Gupta, A., Jarząb, B., Capdevila, J., Shumaker, R., & Hussein, Z. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12907 · Cited by 83
Une, N., Takano-Kasuya, M., Kitamura, N., Ohta, M., Inose, T., Kato, C., Nishimura, R., Tada, H., Miyagi, S., Ishida, T., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01503-z · Cited by 82
Leveraging the immune system to treat advanced thyroid cancers
French, J. D., Bible, K. C., Spitzweg, C., Haugen, B. R., & Ryder, M. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30277-7 · Cited by 81
Alsina, A. E., Kudo, M., Vogel, A., Cheng, A., Tak, W. Y., Ryoo, B., Evans, T. R. J., López, C., Daniele, B., Misir, S., et al. (2019) · Liver Cancer · doi:10.1159/000504624 · Cited by 80
Radiofrequency ablation: mechanisms and clinical applications
Wu, J., Zhou, Z., Huang, Y., Deng, X., Zheng, S., He, S., Huang, G., Hu, B., Shi, M., Liao, W., et al. (2024) · MedComm · doi:10.1002/mco2.746 · Cited by 80
Kim, J. J., McFarlane, T., Tully, S., & Wong, W. W. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0501 · Cited by 78
Mou, L., Tian, X., Zhou, B., Zhan, Y., Chen, J., Lu, Y., Deng, J., Deng, Y., Wu, Z., Li, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752725 · Cited by 77
Novel approaches for molecular targeted therapy against hepatocellular carcinoma
Eso, Y., & Marusawa, H. (2018) · Hepatology Research · doi:10.1111/hepr.13181 · Cited by 76
Molecular Markers Guiding Thyroid Cancer Management
Nylén, C., Mechera, R., Maréchal-Ross, I., Tsang, V., Chou, A. S. Y., Gill, A. J., Clifton-Bligh, R. J., Robinson, B. G., Sywak, M. S., Sidhu, S. B., et al. (2020) · Cancers · doi:10.3390/cancers12082164 · Cited by 73
Hussein, Z., Mizuo, H., Hayato, S., Namiki, M., & Shumaker, R. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0403-4 · Cited by 73
The roles and role-players in thyroid cancer angiogenesis
Rajabi, S., Dehghan, M. H., Dastmalchi, R., Mashayekhi, F. J., Salami, S., & Hedayati, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0537 · Cited by 68
Matsuki, M., Adachi, Y., Ozawa, Y., Kimura, T., Hoshi, T., Okamoto, K., Tohyama, O., Mitsuhashi, K. O., Yamaguchi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13169 · Cited by 68
Self-citationShimose, S., Kawaguchi, T., Tanaka, M., Iwamoto, H., Miyazaki, K., Moriyama, E., Suzuki, H., Niizeki, T., Shirono, T., Nakano, M., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11758 · Cited by 68
Ichikawa, K., Miyano, S. W., Minoshima, Y., Matsui, J., & Funahashi, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-59853-z · Cited by 66
Self-citationLenvatinib for Hepatocellular Carcinoma: A Literature Review
Hatanaka, T., Naganuma, A., & Kakizaki, S. (2021) · Pharmaceuticals · doi:10.3390/ph14010036 · Cited by 66
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo
Ferrari, S. M., Bocci, G., Desidero, T. D., Elia, G., Ruffilli, I., Ragusa, F., Orlandi, P., Paparo, S. R., Patrizio, A., Piaggi, S., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6306 · Cited by 65
Huang, S., Ma, Z., Zhou, Q., Wang, A., Gong, Y., Li, Z., Wang, S., Yan, Q., Wang, D., Hou, B., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69969 · Cited by 64
Tan, W., Zhang, K., Chen, X., Yang, L., Zhu, S., Wei, Y., Xie, Z., Chen, Y., & Shang, C. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.03.012 · Cited by 63
Kudo, M., Finn, R. S., Qin, S., Han, K., Ikeda, K., Cheng, A., Vogel, A., Tovoli, F., Ueshima, K., Aikata, H., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.006 · Cited by 63
Vogel, A., Frenette, C. T., Sung, M. W., Daniele, B., Baron, A. D., Chan, S. L., Blanc, J. F., Tamai, T., Ren, M., Lim, H. J., et al. (2021) · Liver Cancer · doi:10.1159/000516490 · Cited by 61
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
Ogasawara, S., Mihara, Y., Kondo, R., Kusano, H., Akiba, J., & Yano, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13802 · Cited by 61
Kodama, K., Kawaoka, T., Namba, M., Uchikawa, S., Ohya, K., Morio, K., Nakahara, T., Murakami, E., Yamauchi, M., Hiramatsu, A., et al. (2019) · Oncology · doi:10.1159/000499715 · Cited by 59
Self-citationPhase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)
Higashiyama, T., Sugino, K., Hara, H., Ito, K., Nakashima, N., Onoda, N., Tori, M., Katoh, H., Kiyota, N., Ota, I., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.044 · Cited by 59
Gungor, M. Z., Uysal, M., & Şentürk, Ş. (2022) · Cancers · doi:10.3390/cancers14040940 · Cited by 58
Makker, V., Aghajanian, C. A., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., Messing, M. J., Dutta, L., Dutcus, C. E., Huang, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01021 · Cited by 58
Yu, T., Yu, J., Lu, L., Zhang, Y., Zhou, Y., Zhou, Y., Huang, F., Sun, L., Guo, Z., Hou, G., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00605-0 · Cited by 58
Chen, R., Li, Q., Xu, S., Ye, C., Tian, T., Jiang, Q., Shan, J., & Ruan, J. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02435-4 · Cited by 57
Aoki, T., Kudo, M., Ueshima, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Minami, Y., Tsurusaki, M., et al. (2020) · Cancers · doi:10.3390/cancers12103048 · Cited by 56
Cheng, K., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200514082425 · Cited by 55
Takahashi, S., Tahara, M., Ito, K., Tori, M., Kiyota, N., Yoshida, K., Sakata, Y., & Yoshida, A. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01433-8 · Cited by 55
Oura, K., Morishita, A., Hamaya, S., Fujita, K., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032805 · Cited by 54
Nakamichi, S., Nokihara, H., Yamamoto, N., Yamada, Y., Honda, K., Tamura, Y., Wakui, H., Sasaki, T., Yusa, W., Fujino, K., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2899-0 · Cited by 54
Lorusso, L., Pieruzzi, L., Biagini, A., Sabini, E., Valerio, L., Giani, C., Passannanti, P., Contillo, B. P., Battaglia, V., Mazzeo, S., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s84625 · Cited by 53
Ozeki, T., Nagahama, M., Fujita, K., Suzuki, A., Sugino, K., Ito, K., & Miura, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-41820-y · Cited by 53
Lee, Y. S., Kim, S., Kim, B., Chang, H. J., Kim, S. Y., Park, K. C., Park, K. C., & Chang, H. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.003 · Cited by 51
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
Novello, S., Califano, R., Reinmuth, N., Tamma, A. V., & Puri, T. (2023) · The Oncologist · doi:10.1093/oncolo/oyac264 · Cited by 50
Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study
Iwasaki, H., Yamazaki, H., Takasaki, H., Suganuma, N., Nakayama, H., Toda, S., & Masudo, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.9553 · Cited by 50
Taylor, M. H., Takahashi, S., Capdevila, J., Tahara, M., Leboulleux, S., Kiyota, N., Dutcus, C. E., Xie, R., Robinson, B. G., Sherman, S. I., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0779 · Cited by 50
Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
Tomonari, T., Sato, Y., Tanaka, H., Tanaka, T., Taniguchi, T., Sogabe, M., Okamoto, K., Miyamoto, H., Muguruma, N., Saito, Y., et al. (2020) · Medicine · doi:10.1097/md.0000000000022782 · Cited by 49
Self-citation
Metadata
- Authors
- Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
- Affiliations
- Eisai (Japan) (JP)
- Eisai (United States) (US)
- Corresponding author
- Funahashi, Yasuhiro
- ORCID
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC4177084
- OpenAlex
- W2094109552
- Cited by
- 475
- References
- 50
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.